Evidence map›Paper›PMID 40636346›Full record

ArticleiLIVER2022

Effects of Raf kinase inhibitor protein on biological characteristics of hepatocellular carcinoma cells and its potential therapeutic effects.

Zhang Lin, Zhu Jianhua, Wu Kai, Hou Yanhong, Liu Haorun

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Zhang LinDepartment of Gastroenterology, Eighth Medical Center, General Hospital of Chinese PLA, Beijing 100091, China.
Zhu JianhuaDepartment of Gastroenterology, Eighth Medical Center, General Hospital of Chinese PLA, Beijing 100091, China.
Wu KaiDepartment of Gastroenterology, Eighth Medical Center, General Hospital of Chinese PLA, Beijing 100091, China.
Hou YanhongDepartment of Gastroenterology, Eighth Medical Center, General Hospital of Chinese PLA, Beijing 100091, China.
Liu HaorunDepartment of Gastroenterology, Eighth Medical Center, General Hospital of Chinese PLA, Beijing 100091, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Raf kinase inhibitor protein (RKIP) is an important member of the phosphatidylethanolamine-binding protein family. This study investigated the inhibitory effect of RKIP on the malignant biological behavior of liver cancer cells in vivo and in vitro. Methods: An RKIP gene expression vector was constructed using the pcDNA3.1 vector and transfected into human hepatoma cell line HepG2 to overexpress the RKIP gene. Growth, proliferation, the cell cycle, apoptosis, migration, and invasion of the cell line were analyzed. For in vivo experiments, the vector was transfected into tumor tissue of hepatoma-bearing animals and then tumor growth was analyzed and compared with the control to assess its anti-tumor effect. Results: Compared with the control group, cell growth in the RKIP gene transfection group (HEP-RKIP) was significantly slower. The average colony formation rate of the HEP-RKIP group was significantly lower than that of the other two groups ( Conclusion: RKIP inhibits malignant biological behavior of liver cancer cells in vitro and has a tumor inhibitory effect in vivo, which may be a potential target for gene therapy of liver cancer.

Indexed as

Gene therapyPrimary liver cancerRKIP geneTumor suppressor gene

Identifiers

PMID40636346
PMCPMC12212733

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.